Related Articles
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition
Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Metastatic breast cancer with double heterozygosity for the <em>BRCA1 </em>and <em>BRCA2</em> genes responding to olaparib: A case report
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin